[Broncaspin in respiratory diseases in pediatrics. Clinical contribution].

Abstract

Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect. The preparation was outstanding for speed of action, local and general tolerance, and the absence of haematological, hepatic or renal side-effects. The new drug is considered to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

• Authors: P Mora, P Levi, G Marostica
• Journal: Minerva medica (Minerva Med) Vol. 72 Issue 7 Pg. 417-22 (Feb 28 1981) ISSN: 0026-4806 [Print] Italy
• Vernacular Title: Il Broncaspin nelle affezioni respiratorie in pediatria. Contributo clinico.
• PMID: 7017493 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Aspirin
• guacetisal

Topics

• Aspirin (analogs & derivatives, therapeutic use)
• Bronchitis (drug therapy)
• Bronchopneumonia (drug therapy)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Cough (drug therapy)
• Dyspnea (drug therapy)
• Fever (drug therapy)
• Humans
• Infant
• Laryngitis (drug therapy)
• Pharyngitis (drug therapy)
• Respiratory Tract Diseases (drug therapy)
• Tracheitis (drug therapy)